Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus

다국어 초록 (Multilingual Abstract)

Background/Aims: Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistanthepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after ADV rescuetherapy in decompensated patients infected with lamivudine-resistant HBV.
Methods: In total, 128 patients with a decompensated state and lamivudine-resistant HBV were treated with ADV at adosage of 10 mg/day for a median of 33 months in this multicenter cohort study.
Results: Following ADV treatment, 86 (72.3%) of 119 patients experienced a decrease in Child-Pugh score of at least 2points, and the overall end-stage liver disease score decreased from 16±5 to 14±10 (mean ± SD, P<0.001) during thefollow-up period. With ADV treatment, 67 patients (56.3%) had undetectable serum HBV DNA (detection limit, 0.5 pg/mL). Virologic breakthrough occurred in 38 patients (36.1%) and 9 patients had a suboptimal ADV response. Theoverall survival rate was 89.9% (107/119), and a suboptimal response to ADV treatment was associated with both noimprovement in Child-Pugh score (≥2 points; P=0.001) and high mortality following ADV rescue therapy (P=0.012).
Conclusions: Three years of ADV treatment was effective and safe in decompensated patients with lamivudine-resistant HBV.

참고문헌 (Reference)

1 Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B" 44 : 283-290, 2006

2 Allen MI, "Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine" 37 : 3338-3347, 1999

3 Bae SH, "Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis" 20 : 1527-1532, 2005

4 van Bömmel F, "Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy" 44 : 318-325, 2006

5 de Jongh FE, "Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver" 103 : 1630-1635, 1992

6 Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil" 55 : 1488-1495, 2006

7 Osborn MK, "Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list" 5 : 1454-1461, 2007

8 Locarnini S., "Molecular virology and the development of resistant mutants: implications for therapy" 25 (25): 9-19, 2005

9 Perrillo R, "Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus" 109 : 908-916, 1995

10 Yao FY, "Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection" 33 : 301-307, 2000

11 Villeneuve JP, "Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B" 31 : 207-210, 2000

12 Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease" 351 : 1521-1531, 2004

13 Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy" 43 : 1385-1391, 2006

14 Beasley RP., "Hepatitis B virus. The major etiology of hepatocellular carcinoma" 61 : 1942-1956, 1988

15 Lavanchy D., "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures" 11 : 97-107, 2004

16 Bain VG, "Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation" 62 : 1456-1462, 1996

17 Liaw YF, "Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group" 119 : 172-180, 2000

18 Fontana RJ, "Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy" 123 : 719-727, 2002

19 Tseng PL, "Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis" 12 : 386-392, 2005

20 van Bömmel F, "Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection" 40 : 1421-1425, 2004

21 Lok AS, "Chronic hepatitis B" 45 : 507-539, 2007

22 Kapoor D, "Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis" 33 : 308-312, 2000

23 Schiff ER, "Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients" 38 : 1419-1427, 2003

24 Schiff E, "Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results" 13 : 349-360, 2007

25 Marcellin P, "Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B" 348 : 808-816, 2003

26 Hadziyannis SJ, "Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B" 348 : 800-807, 2003

27 Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B" 126 : 91-101, 2004

28 Perrillo R, "Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus" 126 : 81-90, 2004

29 Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B" 45 : 307-313, 2007

30 Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update" 4 : 936-962, 2006

31 Perrillo RP, "A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B" 33 : 424-432, 2001

32 Kamath PS, "A model to predict survival in patients with endstage liver disease" 33 : 464-470, 2001

33 Malinchoc M, "A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts" 31 : 864-871, 2000